UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2015 (May 7, 2015)
MISONIX, INC.
(Exact name of registrant as specified in its charter)
| New York | 1-10986 | 11-2148932 | ||
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer | ||
| incorporation) | Identification No.) |
| 1938 New Highway, Farmingdale, NY | 11735 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (631) 694-9555
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On May 7, 2015, MISONIX, INC. (“Misonix”) issued a press release announcing its financial results for the three months ended March 31, 2015. The press release is attached hereto as Exhibit 99.1. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of Misonix, whether made before or after the date of this report, regardless of any general incorporation language in the filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit 99.1 | Press Release of MISONIX, INC., dated May 7, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 7, 2015 | MISONIX, INC. | |
| By: | /s/ Richard A. Zaremba | |
| Richard A. Zaremba | ||
| Senior Vice President and Chief Financial Officer | ||
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release of MISONIX, INC., dated May 7, 2015 |
Exhibit 99.1
Misonix, Inc. Announces THIRD Quarter
Fiscal Year 2015 Financial Results
Third Quarter Net Revenues UP 24%;
Nine Month Net Revenue UP 35%;
Third Quarter BoneScalpeltm Revenue UP 27%;
| Investor Relations Contacts: | ||
| Misonix Contact: | Lytham Partners, LLC | |
| Richard Zaremba | Robert Blum, Joe Dorame, Joe Diaz | |
| 631-694-9555 | 602-889-9700 | |
|
invest@misonix.com |
mson@lythampartners.com |
FARMINGDALE, NY, May 7, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the third quarter of fiscal 2015, ended March 31, 2015.
Highlights for the third quarter fiscal 2015 included:
Third Quarter Fiscal 2015 Financial Results
Total revenue for the three months ended March 31, 2015 was $5.3 million, a 24% increase, when compared to $4.3 million for the same period in fiscal 2014. The increase was attributable to a 27% increase in BoneScalpel revenue to $2.2 million, a 30% increase in SonaStar revenue to $2.0 million and a 16% increase in SonicOne revenue to $847,000.
There were 50 BoneScalpel units sold or consigned worldwide during third quarter fiscal 2015 compared to 38 BoneScalpel units sold or consigned during the third quarter of fiscal 2014. BoneScalpel disposable sales in the United States increased 52% to $1.1 million during third quarter fiscal 2015 compared to the same period in fiscal 2014. There were 34 SonaStar units sold worldwide during third quarter fiscal 2015 compared to 20 SonaStar units sold during the third quarter of fiscal 2014. SonicOne disposable revenue increased 62% to $607,000 for the third quarter of fiscal 2015. Operating expenses for the three months increased by approximately $1 million as the Company invested in expanding its IT capabilities and continued to invest in sales and marketing primarily through the hiring of clinical applications specialists.
During the quarter, the Company received other income in the form of royalty payments from Covidien plc totaling $1.0 million.
The Company reported net income of approximately $454,000, or $0.05 earnings per diluted share, for third quarter fiscal 2015 compared to net income of $429,000, or $0.05 earnings per diluted share, for the same period in fiscal 2014.
Nine Months Fiscal 2015 Financial Results
Total revenue for the nine months ended March 31, 2015 was $15.4 million, a 35% increase, when compared to $11.5 million for the same period in fiscal 2014. The increase was attributable to a 42% increase in BoneScalpel revenue to $7.4 million, a 35% increase in SonaStar revenue to $5.3 million and a 32% increase in SonicOne revenue to $2.3 million.
The Company reported net income of approximately $1.7 million, or $0.21 per diluted share, for the nine months ended March 31, 2015 compared to net income of $4,000, or $0.00 per diluted share, for the same period in fiscal 2014.
Michael A. McManus Jr., President and CEO stated, "The second half of fiscal year 2015 has started off very strong with revenue increases of 24% and 35% for the third quarter and the nine months respectively. We continue to make consistent progress in penetrating our markets, both domestically and internationally. BoneScalpel units sold or consigned during the quarter increased 31% to 50 units versus 38 units sold or consigned in the comparable quarter last year. The continuing professional efforts over the past two years to refine our sales and marketing strategies are paying off as we consistently increase product placements domestically and sales internationally. As we continue to increase product placements and sales our recurring revenue now accounts for 57% of overall revenue and enhances the credibility of our operating model. Our business is driving revenue, generating solid cash flow and profitability.
“We are particularly pleased with the growing acceptance of our SonicOne O.R. and SonaStar products,” continued Mr. McManus. “The ability of the SonicOne O.R. to safely and effectively debride chronic wounds and burns and accelerate healing not only provides an improved outcome for patients, but also provides a cost benefit for the hospital utilizing the technology. The SonicOne O.R. was recognized at the recent North American Burn Association National Conference in Chicago, Illinois, with a presentation by Abraham Houng, MD, associate program director for the Division of Burn Surgery at Saint Barnabas Medical Center in Livingston, New Jersey. Dr. Houng said, ‘Our expanding experience with the SonicOne O.R. system continues to support a growing body of evidence that debridement with SonicOne O.R. is safer, results in significantly less blood loss, and offers other key advantages over other methods.’ The SonicOne O.R. was also recently recognized at the SuperBones/SuperWounds medical conference in Orlando, Florida. These are important recognitions that speak to the beneficial patient outcomes that can be achieved with our leading-edge product. We are also pleased with the growing acceptance of our SonaStar advanced ultrasonic system for precise soft tissue aspiration and powerful removal of osseous structures. Surgeons are increasingly working with these products and generating improved patient outcomes. We believe that both of these products represent competitive advantages for Misonix in large and growing markets.”
Mr. McManus concluded, “We expect the momentum of the first three quarters to continue into the fourth quarter of fiscal 2015. The financial underpinnings of the Company remain strong, with cash and equivalents approaching $9 million, no long-term debt, and operations funded from internally generated cash flow. We look forward to continue to drive solid operational and financial results and to close out fiscal 2015 on a strong note."
Conference Call
The Company has scheduled a conference call today, Thursday, May 7, 2015 at 4:30 pm ET to review the results. Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com.
A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation #10065377. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 30 days.
About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Financial Tables To Follow
MISONIX, INC. And Subsidiaries
Consolidated Balance Sheets
| March 31, 2015 | June 30, 2014 | |||||||
| (derived from audited | ||||||||
| Unaudited | financial statements) | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 8,909,275 | $ | 7,039,938 | ||||
| Accounts receivable, less allowance | ||||||||
| for doubtful accounts of $126,868 and | ||||||||
| $136,868, respectively | 3,517,863 | 3,759,152 | ||||||
| Inventories, net | 4,164,341 | 4,217,350 | ||||||
| Prepaid expenses and other current assets | 529,698 | 367,830 | ||||||
| Total current assets | 17,121,177 | 15,384,270 | ||||||
| Property, plant and equipment, net of accumulated depreciation and | ||||||||
| amortization of $5,399,621 and $4,842,009, respectively | 1,893,873 | 1,517,852 | ||||||
| Goodwill | 1,701,094 | 1,701,094 | ||||||
| Intangible and other assets | 1,106,666 | 924,653 | ||||||
| Total assets | $ | 21,822,810 | $ | 19,527,869 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,023,492 | $ | 1,650,323 | ||||
| Accrued expenses and other current liabilities | 1,357,223 | 1,457,250 | ||||||
| Total current liabilities | 2,380,715 | 3,107,573 | ||||||
| Deferred income | 28,125 | 51,318 | ||||||
| Deferred lease liability | 4,154 | 16,614 | ||||||
| Total liabilities | 2,412,994 | 3,175,505 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' equity: | ||||||||
| Capital stock, $0.01 par value - shares authorized 20,000,000, 7,835,345 and | ||||||||
| 7,412,096 shares issued and 7,710,363 and 7,334,536 shares | ||||||||
| outstanding, respectively | 78,353 | 74,121 | ||||||
| Additional paid-in capital | 30,019,375 | 28,169,622 | ||||||
| Accumulated deficit | (9,741,652 | ) | (11,480,386 | ) | ||||
| Treasury stock, at cost, 124,982 and 77,560 shares, respectively | (946,260 | ) | (410,993 | ) | ||||
| Total stockholders' equity | 19,409,816 | 16,352,364 | ||||||
| Total liabilities and stockholders' equity | $ | 21,822,810 | $ | 19,527,869 | ||||
MISONIX, INC. and Subsidiaries
Condensed Consolidated Statements of Operations
Unaudited
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Net sales | $ | 5,314,797 | $ | 4,284,645 | $ | 15,455,142 | $ | 11,482,288 | ||||||||
| Cost of goods sold | 1,670,359 | 1,431,766 | 5,023,639 | 4,006,505 | ||||||||||||
| Gross profit | 3,644,438 | 2,852,879 | 10,431,503 | 7,475,783 | ||||||||||||
| Selling expenses | 2,465,803 | 1,913,795 | 6,570,263 | 5,426,324 | ||||||||||||
| General and administrative expenses | 1,583,399 | 1,176,047 | 4,364,261 | 3,518,288 | ||||||||||||
| Research and development expenses | 407,773 | 406,466 | 1,169,665 | 1,314,373 | ||||||||||||
| Total operating expenses | 4,456,975 | 3,496,308 | 12,104,189 | 10,258,985 | ||||||||||||
| Loss from operations | (812,537 | ) | (643,429 | ) | (1,672,686 | ) | (2,783,202 | ) | ||||||||
| Total other income | 1,025,587 | 825,599 | 3,207,997 | 2,536,258 | ||||||||||||
| Income (loss) from continuing operations before income taxes | 213,050 | 182,170 | 1,535,311 | (246,944 | ) | |||||||||||
| Income tax expense | 8,406 | 8,376 | 56,223 | 13,876 | ||||||||||||
| Net income (loss) from continuing operations | 204,644 | 173,794 | 1,479,088 | (260,820 | ) | |||||||||||
| Net income from discontinued operations, net of tax | 249,696 | 254,976 | 259,646 | 264,926 | ||||||||||||
| Net income | $ | 454,340 | $ | 428,770 | $ | 1,738,734 | $ | 4,106 | ||||||||
| Net income (loss) per share from continuing operations-Basic | $ | 0.03 | $ | 0.02 | $ | 0.20 | $ | (0.04 | ) | |||||||
| Net income per share from discontinued operations-Basic | 0.03 | 0.04 | 0.03 | 0.04 | ||||||||||||
| Net income per share-Basic | $ | 0.06 | $ | 0.06 | $ | 0.23 | $ | 0.00 | ||||||||
| Net income (loss) per share from continuing operations-Diluted | $ | 0.02 | $ | 0.02 | $ | 0.18 | $ | (0.04 | ) | |||||||
| Net income per share from discontinued operations-Diluted | 0.03 | 0.03 | 0.03 | 0.04 | ||||||||||||
| Net income per share-Diluted | $ | 0.05 | $ | 0.05 | $ | 0.21 | $ | 0.00 | ||||||||
| Weighted average common shares-basic | 7,675,520 | 7,249,725 | 7,533,608 | 7,209,037 | ||||||||||||
| Weighted average common shares-diluted | 8,313,674 | 7,930,802 | 8,042,976 | 7,209,037 | ||||||||||||